20
2020-04
作者: ACE
4月14日，第一工園·旺山企業總部港B7棟南樓蘇州藥明檢驗檢測有限責任公司（下稱“藥明生物蘇州檢測”）順利通過首次歐洲藥品管理局（EMA）GMP檢查。藥明生物蘇州檢測是是園內卓越的企業代表，此次通過（EMA）GMP檢查備受媒體關注，第一工園對此表示熱烈的祝賀，并與藥明生物蘇州檢測一同分享這一成果的喜悅。
藥明生物全資子公司蘇州檢測
順利通過首次EMA GMP檢查
WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection
(*Please scroll down for English news.)
中國蘇州
2020年4月14日
關于藥明生物蘇州檢測
關于藥明生物
相關閱讀
1 | |
2 |
WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection
Suzhou, China,
April 14, 2020
WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics (Suzhou) Co., Ltd. has successfully passed its first GMP inspection by the European Medicines Agency (EMA), with no critical findings. This is one of the largest biosafety testing laboratories globally providing critical testing support for the global biologics industry.
The comprehensive inspection included areas directly related tobiosafety testing of a client’s product, as well as WuXi Biologics (Suzhou)’s entire quality system, management system, related instrumentation and equipment. Upon passing the inspection, WuXi Biologics (Suzhou) will be one of a few third-party biosafety testing providers in the Asia-pacific region to be EU certified, which greatly improves the company's recognition from drug regulatory agencies and the reliability of its testing services for clients.This also marks another milestone following WuXi Biologics’ first cGMP biologics drug substance facility, first cGMP biologics drug product facility and first cGMP cell banking facility in China, all approved by the EMA.
About WuXi Biologics (Suzhou)
As one of the largest third-party biosafety testing providers in the Asia-pacific region meeting both international standards (USP, EP, JP) and Chinese standards (CN), WuXi Biologics (Suzhou) offers complete CHO cell line characterization testing services, including mycoplasma, retrovirus and general virus screening, along with adventitious virus detection. The company has a state approved BSL-2 biosafety laboratory, with certificates from both the China National Accreditation Service for Conformity Assessment (CNAS) and the China Inspection Body and Laboratory Mandatory Approval (CMA). The company has its own virus bank and technologies used to prepare high-titer viruses, which enable the establishment of a rigorous viral clearance platform. Since 2015, WuXi Biologics (Suzhou) has successfully completed more than 4,000 tests and 300 projects, including more than 20 submissions for the Biologics License Application (BLA).
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of Dec 31, 2019, there were a total of 250 integrated projects, including 121 projects in pre-clinical development stage, 112 projects in early-phase (phase I and II) clinical development, 16 projects in late-phase (phase III) development and one project in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany and Singapore exceeding 280,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit: www.wuxibiologics.com.
媒體聯系 Media Contact：
藥明生物 WuXi Biologics
黃可博士 Kevin Huang PhD
+86-510-85353705
kevin_huang@wuxibiologics.com
注：本信息不構成藥明生物的信息披露或投資建議
文章來源：藥明生物
圖片來源：版權歸原作者所有
注：本文版權歸原作者所有
更多園區資訊
?點擊這里?
第一工園·甪直智能制造產業園
第一工園·沙家浜智能制造產業園
第一工園·太倉星藥港
『廣告』
免責聲明：
1. 本文所涉及的圖文資料僅供參考，雙方的權利義務等具體以合同及補充協議約定為準，開發商在法律規定的范圍內保有最終解釋權。
2. 凡文章內引用的相關配套及政府規劃內容，不排除因政府相關規劃、規定及本公司未能控制的原因而發生變化，我司因不可抗力對此不作承諾。
3. 部分圖文來自網絡，侵權必刪。